

Biperiden

General:

Biperiden is an antiparkinsonian agent of the anticholinergic type. Biperiden is used for the adjunctive treatment of all forms of Parkinson's disease (postencephalitic, idiopathic, and arteriosclerotic). It seems to exert better effects in the postencephalitic and idiopathic than in the arteriosclerotic type. It relieves muscle rigidity, reduces abnormal sweating and salivation, improves abnormal gait, and to lesser extent, tremor.

The oral bioavailability is only 33 +/- 5% due to extensive first-pass metabolism. In young, healthy volunteers peak plasma concentrations following an oral single dose of 4mg in immediate release form are reached after 1.5 hours. The elimination half-life has been determined as 18.4 hours, and may be prolonged in geriatric patients. After IV dosing of 4mg the elimination half-life is approximately 24 hours.

Indication: Therapy monitoring

Material: 1 ml serum

TAT: 7-10 days*

Method: LCMS

Units: µg/l

Ref.- range: 10.0 - 100.0

For complete list of laboratory test offered at Freiburg Medical Laboratory, please visit <http://www.fml-dubai.com/parameter-listings/>